HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acetaminophen Special Populations Toxicity Data Lacking, NDAC Says

This article was originally published in The Tan Sheet

Executive Summary

There are insufficient data on special populations or disease states to warrant acetaminophen label changes to warn such individuals they may be at increased risk for hepatotoxicity, FDA's Nonprescription Drugs Advisory Committee concluded Sept. 19
Advertisement

Related Content

Acetaminophen “Black Box” Warning Would “Scare” Users, NDAC Rep Says
Acetaminophen “Black Box” Warning Would “Scare” Users, NDAC Rep Says
Acetaminophen “Black Box” Warning Would “Scare” Users, NDAC Rep Says
Acetaminophen “Black Box” Warning Would “Scare” Users, NDAC Rep Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS094543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel